Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft

BMC Complementary and Alternative Medicine

Lu-Ming Liu²  Wei-Dong Shi²  Xiao-Yan Zhu²  Jian-Hua Yin¹ 

[1] Department of Oncology, Second TCM Hospital of Guang Dong province, 60 Heng Fu Road, Guang Zhou, Guang Dong province, China;Department of Integrative Oncology, Cancer Hospital, Fudan University, 270 Dong An Road, Shanghai 200032, China

关键词: CA19-9;    MMPs;    VEGF;    Liver metastasis;    Pancreatic cancer;    Huachansu;   

Others  :  1084977
DOI  :  10.1186/1472-6882-14-483

 received in 2013-11-07, accepted in 2014-09-30,  发布年份 2014

【 摘 要 】

Background

Huachansu injection (HCS) is a water-soluble preparation made from Bufo gargarizans’s skin, which has been widely used in clinics for tumor therapy in China. Though the anti-cancer activity of HCS has been verified through studies in vitro and in vivo, there is little research about its potential anti-metastasis effect. The primary objective of this study was to assess the effects of HCS on both the invasion of pancreatic cancer cells in vitro and on the progression of liver metastasis in vivo in this study.

Methods

HCS anti-metastasis potential was accessed using both assay of Cell viability and invasion in vitro, and then further Establishing xenograft model in nude mice. In the cell-based assay, mRNA and protein expression of MMP-2, MMP-9 and VEGF was detected by semi-quantitative RT-PCR and western blotting. In animal experiment, liver metastasis nodules and change of liver-body ratio was observed. Meanwhile, correlation of the CA19-9 and CEA content in serum with the progression of liver metastasis was analyzed.

Result

We observed that HCS prevented the invasion of cancer cells, with inhibiting the expressions of MMP-2 and MMP-9, and reduced not only the number of metastasis nodules but the ratio of liver-body weight as well. Furthermore, HCS decreased the expression of MMP-2, MMP-9 and VEGF in liver metastasis, while also reducing CA19-9 contents in serum. In addition, correlation analysis indicated that the level of CA19-9 in serum was closely related to the number of liver metastasis nodules.

Conclusion

Our experimental results suggest that HCS has some anti-metastasis potential to suppress the growth of liver metastasis by decreasing the expression of MMP-2 and MMP-9 as well as VEGF.

【 授权许可】

   
2014 Yin et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
• [2]Lundin J, Roberts PJ, Kuusela P, Haglund C: The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994, 69:515-519.
• [3]Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001, 8:123-132.
• [4]DiMagno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma, American Gastroenterological Association. Gastroenterology 1999, 117:1464-1484.
• [5]Sener SF, Fremgen A, Menck HR, Winchester DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189:1-7.
• [6]Kornmann M, Beger HG, Link KH: Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res 2003, 161:180-195.
• [7]Fortner JG: Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg 1984, 199:418-425.
• [8]Smeenk HG, Incrocci L, Kazemier G, van Dekken H, Tran KT, Jeekel J, van Eijck CH: Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg 2005, 22:321-328.
• [9]Stupack DG, Cheresh DA: ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci STKE 2002, 2002:e7.
• [10]Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
• [11]Bhowmick NA, Moses HL: Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15:97-101.
• [12]Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, Sebens T, Kloppel G, Kalthoff H, Folsch UR, Schafer H: Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004, 64:1331-1337.
• [13]Teraoka H, Sawada T, Nishihara T, Yashiro M, Ohira M, Ishikawa T, Nishino H, Hirakawa K: Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer 2001, 85:612-617.
• [14]Maatta M, Soini Y, Liakka A, Autio-Harmainen H: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 2000, 6:2726-2734.
• [15]Qian X, Rothman VL, Nicosia RF, Tuszynski GP: Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res 2001, 7:251-259.
• [16]Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF: The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha (6) beta (1) and cell surface heparan sulfate proteoglycans. Endocrinology 2002, 143:1441-1450.
• [17]Babic AM, Kireeva ML, Kolesnikova TV, Lau LF: CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998, 95:6355-6360.
• [18]Chen KK, Kovarikova A: Pharmacology and toxicology of toad venom. J Pharm Sci 1967, 56:1535-1541.
• [19]Zhang J, Sun Y, Liu JH, Yu BY, Xu Q: Microbial transformation of three bufadienolides by Nocardia sp. and some insight for the cytotoxic structure-activity relationship (SAR). Bioorg Med Chem Lett 2007, 17:6062-6065.
• [20]Gan T, Wu Z, Tian L, Wang Y: Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev 2010, 20(1):CD005096.
• [21]Chen Z, Zhai XF, Su YH, Wan XY, Li J, Xie JM, Gao B: Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer. Zhong Xi Yi Jie He Xue Bao 2003, 1:184-186.
• [22]Wang J, Jin Y, Xu Z, Zheng Z, Wan S: Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in A 549 cells. Exp Biol Med (Maywood) 2009, 234:566-572.
• [23]Qi F, Li A, Inagaki Y, Xu H, Wang D, Cui X, Zhang L, Kokudo N, Du G, Tang W: Induction of apoptosis by cinobufacini preparation through mitochondria- and Fas-mediated caspase-dependent pathways in human hepatocellular carcinoma cells. Food Chem Toxicol 2012, 50:295-302.
• [24]Xiao-yan Z, Zhi-qiang M, Zhen C, Jun-hua L, Ye-hua S, Wun A, Peng W, Jian-qin H, Lu-ming L: Anti-tumor Effects ofD ifferentFractions from C inobutacini in human pancreatic cancer-bearing SW1990 mice. SHJTCM 2009, 43:69-71.
• [25]Xiao-yan Z, Lu-ming L, Zhen C, Jun-hua L, Li-tao X, Zhi-qiang M: Effects of “Huachansu Injecion” combined with Gemcitabine on PANC-1 cell proliferation and cell cycle. SHJTCM 2013, 47:85-88.
• [26]Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol 2008, 14:5210-5216.
• [27]Zuo X, Cui Y: Clinical research progress on the antitumor effects of cinobufacini. China Clin Oncol 2003, 8:232-235.
• [28]Hai-tao D, Yong-he HE: Therapeutic effects of the combination of cinobufacini injection and chemotherapy in big artery for 130 patients with middle and late stages of pancrea cancer. China J New Drugs 2007, 16:1403-1405.
• [29]Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R: Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 2009, 115:5309-5318.
• [30]Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M: Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res 2004, 64:5200-5211.
• [31]Juuti A, Lundin J, Nordling S, Louhimo J, Haglund C: Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 2006, 71:61-68.
• [32]Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18:1135-1149.
• [33]Ruifrok AC, Johnston DA: Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001, 23:291-299.
• [34]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
• [35]Hong Z, Chan K, Yeung HW: Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation, liu-shen-wan, by liquid chromatography. J Pharm Pharmacol 1992, 44:1023-1026.
• [36]Bick RJ, Poindexter BJ, Sweney RR, Dasgupta A: Effects of Chan Su, a traditional Chinese medicine, on the calcium transients of isolated cardiomyocytes: cardiotoxicity due to more than Na, K-ATPase blocking. Life Sci 2002, 72:699-709.
• [37]Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999, 43(Suppl):S42-S51.
• [38]Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G: Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995, 62:407-413.
• [39]Nagakawa Y, Aoki T, Kasuya K, Tsuchida A, Koyanagi Y: Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 2002, 24:169-178.
• [40]Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026.
• [41]Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
• [42]Salmon JS, Lockhart AC, Berlin J: Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest 2005, 23:712-726.
• [43]Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
• [44]Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK: Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989, 110:704-709.